Overview of Antiviral Drug Discovery and Development

Antiviral Drug Discovery for Emerging Diseases and Bioterrorism Threats

Volumn , Issue , 2005, Pages 30-82

  Tseng, Christopher K ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

Alphavirus; Arenavirus; Biodefense; Bunyavirus; Cidofovir; CTP synthetase; Ebola virus; Emerging viruses; Flavivirus; Immunomodulators; IMPDH; Influenza A; OMP decarboxylase; Orthopoxviruses; Ribavirin; SAH hydrolase; Severe acute respiratory syndrome (SARS)

Indexed keywords

EID: 84891029068     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/0471716715.ch3     Document Type: Chapter

References (319)

1. Morens, D. M.; Folkers, G. K.; Fauci, A. S. The challenge of emerging and re-emerging infectious diseases. Nature 2004, 430, 242-249.
2. Feldmann, H.; Czub, M.; Jones, S.; Dick, D.; Garbutt, M.; Grolla, A.; Artsob, H. Emerging and re-emerging infectious diseases. Med. Microbiol. Immunol. 2002, 191, 63-74.
3. Fauci, A. S. Infectious diseases: considerations for the 21st century. Clin. Infect. Dis. 2001, 32, 675-685.
4. Gomez, L.; Clavel, A.; Castillo, J.; Seral, C.; Rubio, C. Emerging and reemerging pathogens. Int. J. Antimicrob. Agents 2000, 16, 335-339.
5. Fraser, C. M. A genomics-based approach to biodefence preparedness. Nat. Rev. Genet. 2004, 5, 23-33.
6. Bronze, M. S.; Greenfield, R. A. Preventive and therapeutic approaches to viral agents of bioterrorism. Drug Discov. Today 2003, 8, 740-745.
7. Mairuhu, A. T. A.; Brandjes, D. P. M.; van Gorp, E. C. M. Treating viral hemorrhagic fever. Idrugs 2003, 6, 1061-1066.
8. Kuiken, T.; Fouchier, R.; Rimmelzwaan, G.; Osterhaus, A. Emerging viral infections in a rapidly changing world. Curr Opin. Biotechnol. 2003, 14, 641-646.
9. Gubler, D. J. The global emergence/resurgence of arboviral diseases as public health problems. Arch. Med. Res. 2002, 33, 330-342.
10. Khabbaz, R. F. Emerging viral infections. Adv. Pediatr. Infect. Dis. 1999, 14, 1-27.
11. Andrei, G.; De Clercq, E. Molecular approaches for the treatment of hemorrhagic fever virus infections. Antiviral Res. 1993, 22, 45-75.
12. De Clercq, E. Molecular targets for antiviral agents. J. Pharmacol. Exp. Ther 2001, 297, 1-10.
13. De Clercq, E. Antiviral agents: characteristic activity spectrum depending on the molecular target with which they interact. Adv. Virus Res. 1993, 42, 1-55.
14. Huggins, J. W. Prospects for treatment of viral hemorrhagic fevers with ribavirin, a broad-spectrum antiviral drug. Rev. Infect. Dis. 1989, 11 (Suppl. 4), S750-S761.
15. Witkowski, J. T.; Robins, R. K.; Sidwell, R. W.; Simon, L. N. Design, synthesis, and broad spectrum antiviral activity of 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxa-mide and related nucleosides. J. Med. Chem. 1972, 15, 1150-1154.
16. Sidwell, R. W.; Huffman, J. H.; Khare, G. P.; Allen, L. B.; Witkowski, J. T.; Robins, R. K. Broad-spectrum antiviral activity of virazole: 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide. Science 1972, 177, 705-706.
17. Sidwell, R. W. Ribavirin: a review of antiviral efficacy. Recent Res. Dev. Antimicrob. Agents Chemother. 1996, 1, 219-256.
18. Bray, M.; Huggins, J. Antiviral therapy of haemorrhagic fevers and arbovirus infections. Antiviral Ther. 1998, 3, 53-79.
19. American Academy of Pediatrics. Reassessment of the indications for ribavirin therapy in respiratory syncytial virus infections. Pediatrics 1996, 97, 137-140.
20. Wray, S. K.; Gilbert, B. E.; Noall, M. W.; Knight, V. Mode of action of ribavirin-effect of nucleotide pool alterations on influenza virus ribonucleoprotein synthesis. Antiviral Res. 1985, 5, 29-37.
21. Streeter, D. G.; Witkowski, J. T.; Khare, G. P.; Sidwell, R. W.; Bauer, R. J.; Robins, R. K.; Simon, L. N. Mechanism of action of 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide (Virazole), a new broad-spectrum antiviral agent. Proc. Natl. Acad. Sci. U.S.A. 1973, 70, 1174-1178.
22. Tam, R. C.; Lau, J. Y. N.; Hong, Z. Mechanisms of action of ribavirin in antiviral therapies. Antiviral Chem. Chemother. 2001, 12, 261-272.
23. Reyes, G. R. Ribavirin: recent insights into antiviral mechanisms of action. Curr. Opin. Drug Discov. Dev. 2001, 4, 651-656.
24. Snell, N. J. C. Ribavirin-current status of a broad spectrum antiviral agent. Expert Opin. Pharmacother. 2001, 2, 1317-1324.
25. Lau, J. Y. N.; Tam, R. C.; Liang, T. J.; Hong, Z. Mechanism of action of ribavirin in the combination treatment of chronic HCV infection. Hepatology 2002, 35, 1002-1009.
26. Picardi, A.; Vespasiani Gentilucci, U.; Zardi, E. M.; D'Avola, D.; Amoroso, A.; Afeltra, A. The role of ribavirin in the combination therapy of hepatitis C virus infection. Curr. Pharm. Des. 2004, 10, 2081-2092.
27. Crotty, S.; Cameron, C.; Andino, R. Ribavirin's antiviral mechanism of action: lethal mutagenesis? J. Mol. Med. 2002, 80, 86-95.
28. Goswami, B. B.; Borek, E.; Sharma, O. K.; Fujitaki, J.; Smith, R. A. The broad spectrum antiviral agent ribavirin inhibits capping of mRNA. Biochem. Biophys. Res. Commun. 1979, 89, 830-836.
29. Wray, S. K.; Smith, R. H. A.; Gilbert, B. E.; Knight, V. Effects of selenazofurin and ribavirin and their 5'-triphosphates on replicative functions of influenza A and influenza B viruses. Antimicrob. Agents Chemother. 1986, 29, 67-72.
30. Wray, S. K.; Gilbert, B. E.; Knight, V. Effect of ribavirin triphosphate on primer generation and elongation during influenza virus transcription in vitro. Antiviral Res. 1985, 5, 39-48.
31. Maag, D.; Castro, C.; Hong, Z.; Cameron, C. E. Hepatitis C virus RNA-dependent RNA polymerase (NS5B) as a mediator of the antiviral activity of ribavirin. J. Biol. Chem. 2001, 276, 46094-46098.
32. Hong, Z.; Ferrari, E.; Wright-Minogue, J.; Skelton, A.; Glue, P.; Zhong, W.; Lau, J. Direct antiviral activity of ribavirin: hepatitis C virus NS5B polymerase incorporates ribavirin triphosphate into nascent RNA products. Hepatology 1999, 30, 773.
33. Cassidy, L. F.; Patterson, J. L. Mechanism of La Crosse virus inhibition by ribavirin. Antimicrob. Agents Chemother. 1989, 33, 2009-2011.
34. Crotty, S.; Maag, D.; Arnold, J. J.; Zhong, W. D.; Lau, J. Y. N.; Hong, Z.; Andino, R.; Cameron, C. E. The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen. Nat. Med. 2000, 6, 1375-1379.
35. Crotty, S.; Cameron, C. E.; Andino, R. RNAvirus error catastrophe: direct molecular test by using ribavirin. Proc. Natl. Acad. Sci. U.S.A. 2001, 98, 6895-6900.
36. Severson, W. E.; Schmaljohn, C. S.; Javadian, A.; Jonsson, C. B. Ribavirin causes error catastrophe during Hantaan virus replication. J. Virol. 2003, 77, 481-488.
37. Eigen, M. Error catastrophe and antiviral strategy. Proc. Natl. Acad. Sci. U.S.A. 2002, 99, 13374-13376.
38. Braun, M.; Vierling, J. M. The clinical and immunologic impact of using interferon and ribavirin in the immunosuppressed host. Liver Transplant. 2003, 9, S79-S89.
39. Tam, R. C.; Pai, B.; Bard, J.; Lim, C.; Averett, D. R.; Phan, U. T.; Milovanovic, T. Ribavirin polarizes human T cell responses towards a Type 1 cytokine profile. J. Hepatol. 1999, 30, 376-382.
40. Hultgren, C.; Milich, D. R.; Weiland, O.; Sallberg, M. The antiviral compound ribavirin modulates the T helper (Th)1/Th2 subset balance in hepatitis B and C virus-specific immune responses. J. Gen. Virol. 1998, 79, 2381-2391.
41. Smee, D. F.; Bailey, K. W.; Sidwell, R. W. Treatment of cowpox virus respiratory infections in mice with ribavirin as a single agent or followed sequentially by cidofovir. Antiviral Chem. Chemother. 2000, 11, 303-309.
42. Heagy, W.; Crumpacker, C.; Lopez, P. A.; Finberg, R. W. Inhibition of immune functions by antiviral drugs. J. Clin. Invest. 1991, 87, 1916-1924.
43. Pankiewicz, K. W. Inhibitors of inosine monophosphate dehydrogenase as potential chemotherapeutic agents. Exp. Opin. Ther. Patents 1999, 9, 55-65.
44. Sidwell, R. W.; Huffman, J. H.; Barnett, B. B.; Pifat, D. Y. In vitro and in vivo Phlebovirus inhibition by ribavirin. Antimicrob. Agents Chemother. 1988, 32, 331-336.
45. Watts, D. M.; Ussery, M. A.; Nash, D.; Peters, C. J. Inhibition of Crimean-Congo hemorrhagic-fever viral infectivity yields in vitro by ribavirin. Am. J. Trop. Med. Hyg. 1989, 41, 581-585.
46. Koff, W. C.; Elm, J. L.; Halstead, S. B. Antiviral effects of ribavirin and 6-mercapto-9-tetrahydro-2-furylpurine against dengue viruses in vitro. Antiviral Res. 1982, 2, 69-79.
47. Morrey, J. D.; Smee, D. F.; Sidwell, R. W.; Tseng, C. Identification of active antiviral compounds against a New York isolate of West Nile virus. Antiviral Res. 2002, 55, 107-116.
48. Morrey, J. D.; Sidwell, R. W.; Smee, D. L.; Day, C. W. Cell line-dependent antiviral activity of ribavirin for West Nile virus. Antiviral Res. 2002, 53, A49.
49. Smee, D. F.; Bray, M.; Huggins, J. W. Antiviral activity and mode of action studies of ribavirin and mycophenolic acid against orthopoxviruses in vitro. Antiviral Chem. Chemother. 2001, 12, 327-335.
50. Doerr, H. W.; Michaelis, M.; Preiser, W.; Cinatl, J. In vitro investigation of potential therapeutics for the severe acute respiratory syndrome (SARS). Antiviral Res. 2004, 62, A59.
51. Canonico, P. G.; Kende, M.; Luscri, B. J.; Huggins, J. W. In vivo activity of antivirals against exotic RNA viral infections. J. Antimicrob. Chemother. 1984, 14, 27-41.
52. Kenyon, R. H.; Canonico, P. G.; Green, D. E.; Peters, C. J. Effect of ribavirin and tributylribavirin on Argentine hemorrhagic fever (Junin virus) in guinea pigs. Anti-microb. Agents Chemother. 1986, 29, 521-523.
53. Koff, W. C.; Pratt, R. D.; Elm, J. L.; Venkateshan, C. N.; Halstead, S. B. Treatment of intracranial dengue virus infections in mice with a lipophilic derivative of ribavirin. Antimicrob. Agents Chemother. 1983, 24, 134-136.
54. Smee, D. F.; Morris, J. L. B.; Barnard, D. L.; Vanaerschot, A. Selective inhibition of arthropod-borne and arenaviruses in vitro by 3'-fluoro-3'-deoxyadenosine. Antiviral Res. 1992, 18, 151-162.
55. McCormick, J. B.; King, I. J.; Webb, P. A.; Scribner, C. L.; Craven, R. B.; Johnson, K. M.; Elliott, L. H.; Belmont-Williams, R. Lassa fever-effective therapy with ribavirin. N. Engl. J. Med. 1986, 314, 20-26.
56. Jahrling, P. B.; Hesse, R. A.; Eddy, G. A.; Johnson, K. M.; Callis, R. T.; Stephen, E. L. Lassa virus infection of rhesus monkeys: pathogenesis and treatment with ribavirin. J. Infect. Dis. 1980, 141, 580-589.
57. Stephen, E. L.; Jahrling, P. B. Experimental Lassa fever virus infection successfully treated with ribavirin. Lancet 1979, 268-269.
58. Jahrling, P. B.; Peters, C. J.; Stephen, E. L. Enhanced treatment of Lassa fever by immune plasma combined with ribavirin in cynomolgus monkeys. J. Infect. Dis. 1984, 149, 420-427.
59. Andrei, G.; De Clercq, E. Inhibitory effect of selected antiviral compounds on arenavirus replication in vitro. Antiviral Res. 1990, 14, 287-300.
60. Weissenbacher, M. C.; Calello, M. A.; Merani, M. S.; McCormick, J. B.; Rodriguez, M. Therapeutic effect of the antiviral agent ribavirin in Junin virus-infection of primates. J. Med. Virol. 1986, 20, 261-267.
61. McKee, K. T.; Huggins, J. W.; Trahan, C. J.; Mahlandt, B. G. Ribavirin prophylaxis and therapy for experimental Argentine hemorrhagic fever. Antimicrob. Agents Chemother. 1988, 32, 1304-1309.
62. Enria, D. A.; Maiztegui, J. I. Antiviral treatment of Argentine hemorrhagic fever. Antiviral Res. 1994, 23, 23-31.
63. Weissenbacher, M. C.; Avila, M. M.; Calello, M. A.; Merani, M. S.; McCormick, J. B.; Rodriguez, M. Effect of ribavirin and immune serum on Junin virus infected primates. Med. Microbiol. Immunol. 1986, 175, 183-186.
64. Kirsi, J. J.; North, J. A.; Mckernan, P. A.; Murray, B. K.; Canonico, P. G.; Huggins, J. W.; Srivastava, P. C.; Robins, R. K. Broad-spectrum antiviral activity of 2-beta-D-ribofuranosylselenazole-4-carboxamide, a new antiviral agent. Antimicrob. Agents Chemother. 1983, 24, 353-361.
65. Lucia, H. L.; Coppenhaver, D. H.; Baron, S. Arenavirus infection in the guinea pig model: antiviral therapy with recombinant interferon-alpha, the immunomodulator CL246,738 and ribavirin. Antiviral Res. 1989, 12, 279-292.
66. Smee, D. F.; Gilbert, J.; Leonhardt, J. A.; Barnett, B. B.; Huggins, J. H.; Sidwell, R. W. Treatment of lethal Pichinde virus infections in weanling LVG/Lak hamsters with ribavirin, ribamidine, selenazofurin, and ampligen. Antiviral Res. 1993, 20, 57-70.
67. Huggins, J. W.; Robins, R. K.; Canonico, P. G. Synergistic antiviral effects of ribavirin and the C-nucleoside analogs tiazofurin and selenazofurin against togaviruses, bunya-viruses, and arenaviruses. Antimicrob. Agents Chemother. 1984, 26, 476-480.
68. Burns, N. J.; Barnett, B. B.; Huffman, J. H.; Dawson, M. I.; Sidwell, R. W.; De Clercq, E.; Kende, M. A newly developed immunofluorescent assay for determining the Pichinde virus inhibitory effects of selected nucleoside analogs. Antiviral Res. 1988, 10, 89-98.
69. Murphy, M. E.; Kariwa, H.; Mizutani, T.; Yoshimatsu, K.; Arikawa, J.; Takashima, I. In vitro antiviral activity of lactoferrin and ribavirin upon hantavirus. Arch. Virol. 2000, 145, 1571-1582.
70. Murphy, M. E.; Kariwa, H.; Mizutani, T.; Tanabe, H.; Yoshimatsu, K.; Arikawa, J.; Takashima, I. Characterization of in vitro and in vivo antiviral activity of lactoferrin and ribavirin upon hantavirus. J. Vet. Med. Sci. 2001, 63, 637-645.
71. Huggins, J. W.; Kim, G. R.; Brand, O. M.; McKee, K. T. Ribavirin therapy for Hantaan virus-infection in suckling mice. J. Infect. Dis. 1986, 153, 489-497.
72. Paragas, J.; Whitehouse, C. A.; Endy, T. P.; Bray, M. A simple assay for determining antiviral activity against Crimean-Congo hemorrhagic fever virus. Antiviral Res. 2004, 62, 21-25.
73. Tignor, G. H.; Hanham, C. A. Ribavirin efficacy in an in vivo model of Crimean-Congo hemorrhagic fever virus (CCHF) infection. Antiviral Res. 1993, 22, 309-325.
74. Peters, C. J.; Reynolds, J. A.; Slone, T. W.; Jones, D. E.; Stephen, E. L. Prophylaxis of Rift Valley fever with antiviral drugs, immune serum, an interferon inducer, and a macrophage activator. Antiviral Res. 1986, 6, 285-297.
75. Kende, M.; Alving, C. R.; Rill, W. L.; Swartz, G. M.; Canonico, P. G. Enhanced efficacy of liposome-encapsulated ribavirin against Rift Valley fever virus infection in mice. Antimicrob. Agents Chemother. 1985, 27, 903-907.
76. Kende, M.; Lupton, H. W.; Rill, W. L.; Levy, H. B.; Canonico, P. G. Enhanced therapeutic efficacy of poly(ICLC) and ribavirin combinations against Rift Valley fever virus infection in mice. Antimicrob. Agents Chemother. 1987, 31, 986-990.
77. Garcia, S.; Crance, J. M.; Billecocq, A.; Peinnequin, A.; Jouan, A.; Bouloy, M.; Garin, D. Quantitative real-time PCR detection of Rift Valley fever virus and its application to evaluation of antiviral compounds. J. Clin. Microbiol. 2001, 39, 4456-4461.
78. Crance, J. M.; Gratier, D.; Guimet, J.; Jouan, A. Inhibition of sandfly fever Sicilian virus (Phlebovirus) replication in vitro by antiviral compounds. Res. Virol. 1997, 148, 353-365.
79. Sidwell, R. W.; Huffman, J. H.; Barnard, D. L.; Smee, D. F.; Warren, R. P.; Chirigos, M. A.; Kende, M.; Huggins, J. Antiviral and immunomodulating inhibitors of experimentally induced Punta Toro virus infections. Antiviral Res. 1994, 25, 105-122.
80. Smee, D. F.; Alaghamandan, H. A.; Kini, G. D.; Robins, R. K. Antiviral activity and mode of action of ribavirin 5'-sulfamate against Semliki Forest virus. Antiviral Res. 1988, 10, 253-262.
81. De Clercq, E.; Cools, M.; Balzarini, J.; Snoeck, R.; Andrei, G.; Hosoya, M.; Shigeta, S.; Ueda, T.; Minakawa, N.; Matsuda, A. Antiviral activities of 5-ethynyl-1-beta-D-ribo-furanosylimidazole-4-carboxamide and related-compounds. Antimicrob. Agents Che-mother. 1991, 35, 679-684.
82. De Clercq, E.; Murase, J.; Marquez, V. E. Broad-spectrum antiviral and cytocidal activity of cyclopentenylcytosine, a carbocyclic nucleoside targeted at CTP synthetase. Biochem. Pharmacol. 1991, 41, 1821-1829.
83. van Tiel, F. H.; Harmsen, M.; Kraaijeveld, C. A.; Snippe, H. Inhibition of Semliki Forest virus multiplication by ribavirin-a potential method for the monitoring of antiviral agents in serum. J. Virol. Methods 1986, 14, 119-125.
84. Briolant, S.; Garin, D.; Scaramozzino, N.; Jouan, A.; Crance, J. M. In vitro inhibition of Chikungunya and Semliki Forest viruses replication by antiviral compounds: synergistic effect of interferon-alpha and ribavirin combination. Antiviral Res. 2004, 61, 111-117.
85. Crance, J. M.; Scaramozzino, N.; Jouan, A.; Garin, D. Interferon, ribavirin, 6-azauridine and glycyrrhizin: antiviral compounds active against pathogenic flaviviruses. Antiviral Res. 2003, 58, 73-79.
86. Neyts, J.; Meerbach, A.; McKenna, P.; De Clercq, E. Use of the yellow fever virus vaccine strain 17D for the study of strategies for the treatment of yellow fever virus infections. Antiviral Res. 1996, 30, 125-132.
87. Diamond, M. S.; Zachariah, M.; Harris, E. Mycophenolic acid inhibits dengue virus infection by preventing replication of viral RNA. Virology 2002, 304, 211-221.
88. Sbrana, E.; Xiao, S. Y.; Guzman, H.; Ye, M. G.; Travassos da Rosa, A. P. A.; Tesh, R. B. Efficacy of post-exposure treatment of yellow fever with ribavirin in a hamster model of the disease. Am. J. Trop. Med. Hyg., 2004, 71, 306-312.
89. Buckwold, V. E.; Wei, J. Y.; Wenzel-Mathers, M.; Russell, J. Synergistic in vitro interactions between alpha interferon and ribavirin against bovine viral diarrhea virus and yellow fever virus as surrogate models of hepatitis C virus replication. Antimicrob. Agents Chemother. 2003, 47, 2293-2298.
90. Malinoski, F. J.; Hasty, S. E.; Ussery, M. A.; Dalrymple, J. M. Prophylactic ribavirin treatment of dengue type 1 infection in rhesus monkeys. Antiviral Res. 1990, 13, 139-149.
91. Jordan, I.; Briese, T.; Fischer, N.; Lau, J. Y. N.; Lipkin, W. I. Ribavirin inhibits West Nile virus replication and cytopathic effect in neural cells. J. Infect. Dis. 2000, 182, 1214-1217.
92. Baker, R.; Bray, M.; Huggins, J. W. Potential antiviral therapeutics for smallpox, monkeypox and other orthopoxvirus infections. Antiviral Res. 2003, 57, 13-23.
93. Jahrling, P. B.; Zaucha, G. M.; Huggins, J. W. Countermeasures to the reemergence of smallpox virus as an agent of bioterrorism. In Emerging Infections 4, Scheld, W. M.; Craig, W. A.; Hughes, J. M. (Eds.). ASM Press, Washington, DC, 2000, pp 187-200.
94. Kern, E. R. In vitro activity of potential anti-poxvirus agents. Antiviral Res. 2003, 57, 35-40.
95. Smee, D. F.; Wong, M. H.; Bailey, K. W.; Beadle, J. R.; Hostetler, K. Y.; Sidwell, R. W. Effects of four antiviral substances on lethal vaccinia virus (IHD strain) respiratory infections in mice. Int. J. Antimicrob. Agents 2004, 23, 430-437.
96. Borio, L.; Inglesby, T.; Peters, C. J.; Schmaljohn, A. L.; Hughes, J. M.; Jahrling, P. B.; Ksiazek, T.; Johnson, K. M.; Meyerhoff, A.; Toole, T.; Ascher, M. S.; Bartlett, J.; Breman, J. G.; Eitzen, E. M.; Hamburg, M.; Hauer, J.; Henderson, D. A.; Johnson, R. T.; Kwik, G.; Layton, M.; Lillibridge, S.; Nabel, G. J.; Osterholm, M. T.; Perl, T. M.; Russell, P.; Tonat, K. Hemorrhagic fever viruses as biological weapons: medical and public health management. JAMA 2002, 287, 2391-2405.
97. Fisher-Hoch, S. P.; Gborie, S.; Parker, L.; Huggins, J. Unexpected adverse reactions during a clinical trial in rural West Africa. Antiviral Res. 1992, 19, 139-147.
98. Kilgore, P. E.; Ksiazek, T. G.; Rollin, P. E.; Mills, J. N.; Villagra, M. R.; Montenegro, M. J.; Costales, M. A.; Paredes, L. C.; Peters, C. J. Treatment of Bolivian hemorrhagic fever with intravenous ribavirin. Clin. Infect. Dis. 1997, 24, 718-722.
99. Enria, D. A.; Briggiler, A. M.; Levis, S.; Vallejos, D.; Maiztegui, I.; Canonico, P. G. Tolerance and antiviral effect of ribavirin in patients with Argentine hemorrhagic fever. Antiviral Res. 1987, 7, 353-359.
100. Mardani, M.; Jahromi, M. K.; Naieni, K. H.; Zeinali, M. The efficacy of oral ribavirin in the treatment of Crimean-Congo hemorrhagic fever in Iran. Clin. Infect. Dis. 2003, 36, 1613-1618.
101. Fisher-Hoch, S. P.; Khan, J. A.; Rehman, S.; Mirza, S.; Khurshid, M.; McCormick, J. B. Crimean-Congo hemorrhagic fever treated with oral ribavirin. Lancet 1995, 346, 472-475.
102. Athar, M. N.; Baqai, H. Z.; Ahmad, M.; Khalid, M. A.; Bashir, N.; Ahmad, A. M.; Balouch, A. H.; Bashir, K. Short report: Crimean-Congo hemorrhagic fever outbreak in Rawalpindi, Pakistan, February 2002. Am. J. Trop. Med. Hyg. 2003, 69, 284-287.
103. McJunkin, J. E.; Khan, R.; deLos, R.; Parsons, D. L.; Minnich, L. L.; Ashley, R. G.; Tsai, T. F. Treatment of severe La Crosse encephalitis with intravenous ribavirin following diagnosis by brain biopsy. Pediatrics 1997, 99, 261-267.
104. Huggins, J. W.; Hsiang, C. M.; Cosgriff, T. M.; Guang, M. Y.; Smith, J. I.; Wu, Z. O.; LeDuc, J. W.; Zheng, Z. M.; Meegan, J. M.; Wang, Q. N.; Oland, D. D.; Gui, X. E.; Gibbs, P. H.; Yuan, G. H.; Zhang, T. M. Prospective, double-blind, concurrent, placebo-controlled clinical trial of intravenous ribavirin therapy of hemorrhagic fever with renal syndrome. J. Infect. Dis. 1991, 164, 1119-1127.
105. Chapman, L. E.; Mertz, G. J.; Peters, C. J.; Jolson, H. M.; Khan, A. S.; Ksiazek, T. G.; Koster, F. T.; Baum, K. F.; Rollin, P. E.; Pavia, A. T.; Holman, R. C.; Christenson, J. C.; Rubin, P. J.; Behrman, R. E.; Bell, L. J. W.; Simpson, G. L.; Sadek, R. F. Intravenous ribavirin for hantavirus pulmonary syndrome: safety and tolerance during 1 year of open-label experience. Antiviral Ther. 1999, 4, 211-219.
106. Mertz, G. J. ; Miedzinski, L.; Goade, D.; Pavia, A. T.; Hjelle, B.; Hansbarger, C. O.; Levy, H.; Koster, F. T.; Baum, K.; Lindemulder, A.; Wang, W. Q.; Riser, L.; Fernandez, H.; Whitley, R. J. Placebo-controlled, double blind trial of intravenous ribavirin for hantavirus cardiopulmonary syndrome in North America. Clin. Infect. Dis., 2004, 39, 1307-1313.
107. Chong, H. T.; Kamarulzaman, A.; Tan, C. T.; Goh, K. J.; Thayaparan, T.; Kunjapan, R.; Chew, N. K.; Chua, K. B.; Lam, S. K. Treatment of acute Nipah encephalitis with ribavirin. Ann. Neurol. 2001, 49, 810-813.
108. Goldstein, B. M.; Colby, T. D. IMP dehydrogenase: structural aspects of inhibitor binding. Curr. Med. Chem. 1999, 6, 519-536.
109. Markland, W.; McQuaid, T. J.; Jain, J.; Kwong, A. D. Broad-spectrum antiviral activity of the IMP dehydrogenase inhibitor VX-497: a comparison with ribavirin and demonstration of antiviral additivity with alpha interferon. Antimicrob. Agents Chemother. 2000, 44, 859-866.
110. Canonico, P. G.; Jahrling, P. B.; Pannier, W. L. Antiviral efficacy of pyrazofurin against selected RNA viruses. Antiviral Res. 1982, 2, 331-337.
111. Marquez, V. E.; Lim, M. I.; Treanor, S. P.; Plowman, J.; Priest, M. A.; Markovac, A.; Khan, M. S.; Kaskar, B.; Driscoll, J. S. Cyclopentenylcytosine-a carbocyclic nucleoside with antitumor and antiviral properties. J. Med. Chem. 1988, 31, 1687-1694.
112. De Clercq, E. Carbocyclic adenosine analogues as S-adenosylhomocysteine hydrolase inhibitors and antiviral agents: recent advances. Nucleosides Nucleotides 1998, 17, 625-634.
113. Hasobe, M.; Liang, H.; Aultriche, D. B.; Borcherding, D. R.; Wolfe, M. S.; Borchardt, R. T. (1 'R,2'S,3'R)-9-(2',3'-Dihydroxycyclopentan-1'-yl)-adenine and 3-deazaadenine analogs of aristeromycin which exhibit potent antiviral activity with reduced cytotoxicity. Antiviral Chem. Chemother. 1993, 4, 245-248.
114. Hasobe, M.; Mckee, J. G.; Borchardt, R. T. Relationship between intracellular concentration of S-adenosylhomocysteine and inhibition of vaccinia virus replication and inhibition of murine L-929 cell growth. Antimicrob. Agents Chemother. 1989, 33, 828-834.
115. Yuan, C. S.; Saso, Y.; Lazarides, E.; Borchardt, R. T.; Robins, M. J. Recent advances in S-adenosyl-L-homocysteine hydrolase inhibitors and their potential clinical applications. Expert Opin. Ther. Patents 1999, 9, 1197-1206.
116. Wolfe, M. S.; Borchardt, R. T. S-Adenosyl-L-homocysteine hydrolase as a target for antiviral chemotherapy. J. Med. Chem. 1991, 34, 1521-1530.
117. Huggins, J.; Zhang, Z. X.; Bray, M. Antiviral drug therapy of filovirus infections: S-adenosylhomocysteine hydrolase inhibitors inhibit Ebola virus in vitro and in a lethal mouse model. J. Infect. Dis. 1999, 179, S240-S247.
118. Bray, M.; Paragas, J. Experimental therapy of filovirus infections. Antiviral Res. 2002, 54, 1-17.
119. Leyssen, P.; De Clercq, E.; Neyts, J. Perspective for the treatment of infections with Flaviviridae. Clin. Microbiol. Rev. 2000, 13, 67-82.
120. Song, G. Y.; Paul, V.; Choo, H.; Morrey, J.; Sidwell, R. W.; Chu, C. K. Enantiomeric synthesis of D-and L-cyclopentenyl nucleosides and their antiviral activity against West Nile virus. J. Med. Chem. 2001, 44, 3985-3993.
121. Chu, C. K.; Jin, Y. H.; Baker, R. O.; Huggins, J. Antiviral activity of cyclopentenyl nucleosides against orthopox viruses (smallpox, monkeypox and cowpox). Bioorg. Med. Chem. Lett. 2003, 13, 9-12.
122. De Clercq, E. Vaccinia virus inhibitors as a paradigm for the chemotherapy of poxvirus infections. Clin. Microbiol. Rev. 2001, 14, 382-397.
123. De Clercq, E.; Cools, M.; Balzarini, J.; Marquez, V. E.; Borcherding, D. R.; Borchardt, R. T.; Drach, J. C.; Kitaoka, S.; Konno, T. Broad-spectrum antiviral activities of neplanocin-A, 3-deazaneplanocin-A, and their 5'-nor derivatives. Antimicrob. Agents Chemother. 1989, 33, 1291-1297.
124. Tseng, C. K. H.; Marquez, V. E.; Fuller, R. W.; Goldstein, B. M.; Haines, D. R.; Mcpherson, H.; Parsons, J. L.; Shannon, W. M.; Arnett, G.; Hollingshead, M.; Driscoll, J. S. Synthesis of 3-deazaneplanocin-A, a powerful inhibitor of S-adenosylhomocysteine hydrolase with potent and selective in vitro and in vivo antiviral activities. J. Med. Chem. 1989, 32, 1442-1446.
125. Smee, D. F.; Alaghamandan, H. A.; Cottam, H. B.; Jolley, W. B.; Robins, R. K. Antiviral activity of the novel immune modulator 7-thia-8-oxoguanosine. J. Biol. Response Mod. 1990, 9, 24-32.
126. Smee, D. F.; Alaghamandan, H. A.; Jin, A.; Sharma, B. S.; Jolley, W. B. Roles of interferon and natural killer cells in the antiviral activity of 7-thia-8-oxoguanosine against Semliki Forest virus infections in mice. Antiviral Res. 1990, 13, 91-102.
127. Smee, D. F.; Huffman, J. H.; Gessaman, A. C.; Huggins, J. W.; Sidwell, R. W. Prophylactic and therapeutic activities of 7-thia-8-oxoguanosine against Punta Toro virus infections in mice. Antiviral Res. 1991, 15, 229-239.
128. Smee, D. F.; Alaghamandan, H. A.; Gilbert, J.; Burger, R. A.; Jin, A.; Sharma, B. S.; Ramasamy, K.; Revankar, G. R.; Cottam, H. B.; Jolley, W. B.; Robins, R. K. Immu-noenhancing properties and antiviral activity of 7-deazaguanosine in mice. Antimicrob. Agents Chemother. 1991, 35, 152-157.
129. Smee, D. F.; Alaghamandan, H. A.; Ramasamy, K.; Revankar, G. R. Broad-spectrum activity of 8-chloro-7-deazaguanosine against RNA virus infections in mice and rats. Antiviral Res. 1995, 26, 203-209.
130. Revankar, G. R.; Rao, T. S.; Ramasamy, K.; Smee, D. F. Synthesis and broad-spectrum antiviral activity in mice of certain alkyl, alkenyl and ribofuranosyl derivatives of 7-deazaguanine. Nucleosides Nucleotides 1995, 14, 671-674.
131. Bauer, D. J.; St.Vincent, L.; Kempe, C. H.; Downie, A. W. Prophylactic treatment of small pox contacts with N-methylisatin beta-thiosemicarbazone (compound 33T57, marboran). Lancet 1963, 494-496.
132. Fenner, F.; Henderson, D. A.; Arita, I.; Jezek, Z.; Ladnyi, I. D. Smallpox and Its Eradication, World Health Organization, Bethesda, MD, 1988.
133. Bauer, D. J. A history of the discovery and clinical application of antiviral drugs. Br. Med. Bull. 1985, 41, 309-314.
134. Huggins, J. W.; Martinez, M. J.; Hartmann, C. J.; Hensley, L. E.; Jackson, D. L.; Kefauver, D. L.; Kulesh, D. A.; Larsen, T.; Miller, D. M.; Mucker, E. M.; Shamblin, J. D.; Tate, M. K.; Whitehouse, C. A.; Zwiers, S. H.; Jahrling, P. B. Successful cidofovir treatment of smallpox-like disease in variola and monkeypox primate models. Antiviral Res. 2004, 62, A57-A58.
135. De Clercq, E. Cidofovir in the treatment of poxvirus infections. Antiviral Res. 2002, 55, 1-13.
136. De Clercq, E. Cidofovir in the therapy and short-term prophylaxis of poxvirus infections. Trends Pharmacol. Sci. 2002, 23, 456-458.
137. De Clercq, E.; Sakuma, T.; Baba, M.; Pauwels, R.; Balzarini, J.; Rosenberg, I.; Holy, A. Antiviral activity of phosphonylmethoxyalkyl derivatives of purine and pyrimidines. Antiviral Res. 1987, 8, 261-272.
138. Safrin, S.; Cherrington, J.; Jaffe, H. S. Clinical uses of cidofovir. Rev. Med. Virol. 1997, 7, 145-156.
139. Plosker, G. L.; Noble, S. Cidofovir: a review of its use in cytomegalovirus retinitis in patients with AIDS. Drugs 1999, 58, 325-345.
140. Cihlar, T.; Chen, M. S. Identification of enzymes catalyzing two-step phosphorylation of cidofovir and the effect of cytomegalovirus infection on their activities in host cells. Mol. Pharmacol. 1996, 50, 1502-1510.
141. Xiong, X.; Smith, J. L.; Kim, C.; Huang, E. S.; Chen, M. S. Kinetic analysis of the interaction of cidofovir diphosphate with human cytomegalovirus DNA polymerase. Biochem. Pharmacol. 1996, 51, 1563-1567.
142. Hitchcock, M. J. M.; Jaffe, H. S.; Martin, J. C.; Stagg, R. J. Cidofovir, a new agent with potent anti-herpesvirus activity. Antiviral Chem. Chemother. 1996, 7, 115-127.
143. Xiong, X.; Smith, J. L.; Chen, M. S. Effect of incorporation of cidofovir into DNA by human cytomegalovirus DNA polymerase on DNA elongation. Antimicrob. Agents Chemother. 1997, 41, 594-599.
144. De Clercq, E. Towards an effective chemotherapy of virus infections: therapeutic potential of cidofovir [(S)-1-[3-hydroxy-2-(phosphonomethoxy)propyl]cytosine, HPMPC] for the treatment of DNA virus infections. Collect. Czech. Chem. Commun. 1998, 63, 480-506.
145. Naesens, L.; Snoeck, R.; Andrei, G.; Balzarini, J.; Neyts, J.; De Clercq, E. HPMPC (cidofovir), PMEA (adefovir) and related acyclic nucleoside phosphonate analogues: a review of their pharmacology and clinical potential in the treatment of viral infections. Antiviral Chem. Chemother. 1997, 8, 1-23.
146. Cundy, K. C. Clinical pharmacokinetics of the antiviral nucleotide analogues cidofovir and adefovir. Clin. Pharmacokinet. 1999, 36, 127-143.
147. De Clercq, E. Therapeutic potential of HPMPC as an antiviral drug. Rev. Med. Virol. 1993, 3, 85-96.
148. Kern, E. R.; Hartline, C.; Harden, E.; Keith, K.; Rodriguez, N.; Beadle, J. R.; Hostetler, K. Y. Enhanced inhibition of orthopoxvirus replication in vitro by alkoxyalkyl esters of cidofovir and cyclic cidofovir. Antimicrob. Agents Chemother. 2002, 46, 991-995.
149. Keith, K. A.; Hitchcock, M. J. M.; Lee, W. A.; Holy, A.; Kern, E. R. Evaluation of nucleoside phosphonates and their analogs and prodrugs for inhibition of orthopoxvirus replication. Antimicrob. Agents Chemother. 2003, 47, 2193-2198.
150. Buller, R. M.; Owens, G.; Schriewer, J.; Melman, L.; Beadle, J. R.; Hostetler, K. Y. Efficacy of oral active ether lipid analogs of cidofovir in a lethal mousepox model. Virology 2004, 318, 474-481.
151. Smee, D. F.; Sidwell, R. W. A review of compounds exhibiting anti-orthopoxvirus activity in animal models. Antiviral Res. 2003, 57, 41-52.
152. Neyts, J.; De Clercq, E. Efficacy of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)-cytosine for the treatment of lethal vaccinia virus-infections in severe combined immune-deficiency (SCID) mice. J. Med. Virol. 1993, 41, 242-246.
153. Bray, M.; Martinez, M.; Smee, D. F.; Kefauver, D.; Thompson, E.; Huggins, J. W. Cidofovir protects mice against lethal aerosol or intranasal cowpox virus challenge. J. Infect. Dis. 2000, 181, 10-19.
154. Bray, M.; Martinez, M.; Kefauver, D.; West, M.; Roy, C. Treatment of aerosolized cowpox virus infection in mice with aerosolized cidofovir. Antiviral Res. 2002, 54, 129-142.
155. Roy, C. J.; Baker, R.; Washburn, K.; Bray, M. Aerosolized cidofovir is retained in the respiratory tract and protects mice against intranasal cowpox virus challenge. Anti-microb. Agents Chemother. 2003, 47, 2933-2937.
156. Smee, D. F.; Bailey, K. W.; Wong, M. H.; Sidwell, R. W. Intranasal treatment of cowpox virus respiratory infections in mice with cidofovir. Antiviral Res. 2000, 47, 171-177.
157. Smee, D. F.; Bailey, K. W.; Sidwell, R. W. Treatment of lethal vaccinia virus respiratory infections in mice with cidofovir. Antiviral Chem. Chemother. 2001, 12, 71-76.
158. Smee, D. F.; Bailey, K. W.; Wong, M. H.; Sidwell, R. W. Effects of cidofovir on the pathogenesis of a lethal vaccinia virus respiratory infection in mice. Antiviral Res. 2001, 52, 55-62.
159. Smee, D. F.; Bailey, K. W.; Sidwell, R. W. Comparative effects of cidofovir and cyclic HPMPC on lethal cowpox and vaccinia virus respiratory infections in mice. Chemotherapy 2003, 49, 126-131.
160. Smee, D. F.; Sidwell, R. W.; Kefauver, D.; Bray, M.; Huggins, J. W. Characterization of wild-type and cidofovir-resistant strains of camelpox, cowpox, monkeypox, and vaccinia viruses. Antimicrob. Agents Chemother. 2002, 46, 1329-1335.
161. Quenelle, D. C.; Collins, D. J.; Kern, E. R. Efficacy of multiple-or single-dose cidofovir against vaccinia and cowpox virus infections in mice. Antimicrob. Agents Chemother. 2003, 47, 3275-3280.
162. Quenelle, D. C.; Collins, D. J.; Kern, E. R. Cutaneous infections of mice with vaccinia or cowpox viruses and efficacy of cidofovir. Antiviral Res. 2004, 63, 33-40.
163. Smee, D. F.; Bailey, K. W.; Sidwell, R. W. Vaccinia skin lesions in immunosuppressed hairless mice can be treated topically but not parenterally with cidofovir. Antiviral Res. 2003, 57, A79.
164. Huggins, J. W.; Smee, D. F.; Martinez, M. J.; Bray, M. Cidofovir (HPMPC) treatment of monkeypox. Antiviral Res. 1998, 37, A73.
165. Beadle, J. R.; Valiaeva, N.; Brad Wan, W.; Hostetler, K. Y. Direct synthesis of acyclic nucleoside phosphonate alkoxyalkyl monoesters. Antiviral Res. 2004, 62, A66-A67.
166. Keith, K. A.; Wan, W. B.; Ciesla, S. L.; Beadle, J. R.; Hostetler, K. Y.; Kern, E. R. Inhibitory activity of alkoxyalkyl and alkyl esters of cidofovir and cyclic cidofovir against orthopoxvirus replication in vitro. Antimicrob. Agents Chemother. 2004, 48, 1869-1871.
167. Huggins, J. W.; Baker, R. O.; Beadle, J. R.; Hostetler, K. Y. Orally active ether lipid prodrugs of cidofovir for the treatment of smallpox. Antiviral Res. 2002, 53, A66.
168. 14C]cidofovir in MRC-5 human lung fibroblasts is explained by unique cellular uptake and metabolism. Mol. Pharmacol. 2003, 63, 678-681.
169. Ciesla, S. L.; Trahan, J.; Wan, W. B.; Beadle, J. R.; Aldern, K. A.; Painter, G. R.; Hostetler, K. Y. Esterification of cidofovir with alkoxyalkanols increases oral bioavailability and diminishes drug accumulation in kidney. Antiviral Res. 2003, 59, 163-171.
170. Quenelle, D. C.; Collins, D. J.; Wan, W. B.; Beadle, J. R.; Hostetler, K. Y.; Kern, E. R. Oral treatment of cowpox and vaccinia virus infections in mice with ether lipid esters of cidofovir. Antimicrob. Agents Chemother. 2004, 48, 404-412.
171. Katz, E.; Margalith, E.; Winer, B. Inhibition of vaccinia virus growth by the nucleoside analogue 1-β-D-ribofunanosyl-1,2,4-triazole-3-carboxamide (Virazole, ribavirin). J. Gen. Virol. 1976, 32, 327-330.
172. Smee, D. F.; Sidwell, R. W. Anti-cowpox virus activities of certain adenosine analogs, arabinofuranosyl nucleosides, and 2'-fluoro-arabinofuranosyl nucleosides. Nucleosides Nucleotides Nucleic Acids 2004, 23, 375-383.
173. Smee, D. F.; Bailey, K. W.; Sidwell, R. W. Treatment of lethal cowpox virus respiratory infections in mice with 2-amino-7-[(1,3-dihydroxy-2-propoxy)methyl]purine and its orally active diacetate ester prodrug. Antiviral Res. 2002, 54, 113-120.
174. Neyts, J.; De Clercq, E. Efficacy of 2-amino-7-(1,3-dihydroxy-2-propoxymethyl)purine for treatment of vaccinia virus (Orthopoxvirus) infections in mice. Antimicrob. Agents Chemother. 2001, 45, 84-87.
175. 0-deoxyuridine on vaccinia virus (Orthopoxvirus) infections in mice. Antimicrob. Agents Chemother. 2002, 46, 2842-2847.
176. Van Aerschot, A.; Herdewijn, P.; Janssen, G.; Cools, M.; De Clercq, E. Synthesis and antiviral activity evaluation of 3'-fluoro-3'-deoxyribonucleosides: broad-spectrum antiviral activity of 3'-fluoro-3'-deoxyadenosine. Antiviral Res. 1989, 12, 133-150.
177. Keller, B. T.; Borchardt, R. T. Adenosine dialdehyde-a potent inhibitor of vaccinia virus multiplication in mouse L929 cells. Mol. Pharmacol. 1987, 31, 485-492.
178. Ishii, H.; Hasobe, M.; Mckee, J. G.; Aultriche, D. B.; Borchardt, R. T. Synergistic antiviral activity of inhibitors of S-adenosylhomocysteine hydrolase and ribavirin. Antiviral. Chem. Chemother. 1993, 4, 127-130.
179. Kane, E. M.; Shuman, S. Adenosine N-1-oxide inhibits vaccinia virus replication by blocking translation of viral early messenger RNAs. J. Virol. 1995, 69, 6352-6358.
180. Rada, B.; Zgorniak-Nowosielska, I. Site of action of N, N'-bis(methylisatin-beta-thiosemicarbazone)-2-methylpiperazine in the vaccinia virus replication cycle. Acta Virol. 1984, 28, 428-432.
181. Pirrung, M. C. Combinatorial Discovery of Novel Anti-poxvirus Isatin-β-Thiosemicarbazones. (personal communication).
182. Hwang, Y.; Wang, B. B.; Bushman, F. D. Molluscum contagiosum virus topoisomerase: purification, activities, and response to inhibitors. J. Virol. 1998, 72, 3401-3406.
183. Sekiguchi, J.; Stivers, J. T.; Mildvan, A. S.; Shuman, S. Mechanism of inhibition of vaccinia DNA topoisomerase by novobiocin and coumermycin. J. Biol. Chem. 1996, 271, 2313-2322.
184. Da Fonseca, F.; Moss, B. Poxvirus DNA topoisomerase knockout mutant exhibits decreased infectivity associated with reduced early transcription. Proc. Natl. Acad. Sci. U.S.A. 2003, 100, 11291-11296.
185. Sekiguchi, J.; Shuman, S. Novobiocin inhibits vaccinia virus replication by blocking virus assembly. Virology 1997, 235, 129-137.
186. Kim, Y. G.; Muralinath, M.; Brandt, T.; Pearcy, M.; Hauns, K.; Lowenhaupt, K.; Jacobs, B. L.; Rich, A. A role for Z-DNA binding in vaccinia virus pathogenesis. Proc. Natl. Acad. Sci. U.S.A. 2003, 100, 6974-6979.
187. Kim, Y. G.; Lowenhaupt, K.; Oh, D. Y.; Kim, K. K.; Rich, A. Evidence that vaccinia virulence factor ER binds to Z-DNA in vivo: implications for development of a therapy for poxvirus infection. Proc. Natl. Acad. Sci. U.S.A. 2004, 101, 1514-1518.
188. Klemperer, N.; McDonald, W.; Boyle, K.; Unger, B.; Traktman, P. The A20Rprotein is a stoichiometric component of the processive form of vaccinia virus DNA polymerase. J. Virol. 2001, 75, 12298-12307.
189. McDonald, W. F.; Klemperer, N.; Traktman, P. Characterization of aprocessive form of the vaccinia virus DNA polymerase. Virology 1997, 234, 168-175.
190. Byrd, C. A.; Bolken, T. C.; Hruby, D. E. Molecular dissection of the vaccinia virus 17L core protein proteinase. J. Virol. 2003, 77, 11279-11283.
191. Demen, M.; Punjabi, A.; Khanna, R.; Grubisha, O.; Traktman, P. Tyrosine phosphorylation of A17 during vaccinia virus infection: involvement of the H1 phosphatase and the F10 kinase. J. Virol. 1999, 73, 7287-7296.
192. Nichols, R. J.; Traktman, P. Characterization of three paralogous members of the mammalian vaccinia related kinase family. J. Biol. Chem. 2004, 279, 7934-7946.
193. Harrison, S. C.; Alberts, B.; Ehrenfeld, E.; Enquist, L. ; Fineberg, H.; McKnight, S. L.; Moss, B.; O'Donnell, M.; Ploegh, H.; Schmid, S. L.; Walter, K. P.; Theriot, J. Discovery of antivirals against smallpox. Proc. Natl. Acad. Sci. U.S.A. 2004, 101, 11178-11192.
194. La Montagne, J. R.; Simonsen, L.; Taylor, R. J.; Turnbull, J.; Severe acute respiratory syndrome: developing a research response. J. Infect. Dis. 2004, 189, 634-641.
195. Yarnell, A. In search of SARS therapeutics. Chem. Eng. News 2003, 81, 13.
196. 4-hydroxycytidine. Antiviral Chem. Chemother. 2004, 15, 15-22.
197. Cinatl, J.; Morgenstern, B.; Bauer, G.; Chandra, P.; Rabenau, H.; Doerr, H. W. Glycyrrhizin, an active component of liquorice roots, and replication of SARS-associated coronavirus. Lancet 2003, 361, 2045-2046.
198. Morgenstern, B.; Cinatl, J.; Neyts, J.; Bauer, G.; Rabenau, H.; Doerr, H. W. Evaluation of compounds against a novel coronavirus from patients with severe acute respiratory syndrome (SARS). Antiviral Res. 2003, 57, A92.
199. Wu, C. J.; Jan, J. T.; Chen, C. M.; Hsieh, H. P.; Hwang, D. R.; Liu, H. W.; Liu, C. Y.; Huang, H. W.; Chen, S. C.; Hong, C. F.; Lin, R. K.; Chao, Y. S.; Hsu, J. T. A. Inhibition of severe acute respiratory syndrome coronavirus replication by niclosamine. Antimicrob. Agents Chemother. 2004, 48, 2693-2696.
200. Wu, C. Y.; Jan, J. T.; Ma, S. H.; Kuo, C. J.; Juan, H. F.; Cheng, Y. S. E.; Hsu, H. H.; Huang, H. C.; Wu, D.; Brik, A.; Liang, F. S.; Liu, R. S.; Fang, J. M.; Chen, S. T.; Liang, P. H.; Wong, C. H. Small molecules targeting severe acute respiratory syndrome human coronavirus. Proc. Natl. Acad. Sci. U.S.A. 2004, 101, 10012-10017.
201. Hensley, L. E.; Fritz, E. A.; Jahrling, P. B.; Karp, C. L.; Huggins, J. W.; Geisbert, T. W. Interferon-beta 1a and SARS coronavirus replication. Emerging Infect. Dis. 2004, 10, 317-319.
202. Stroher, U.; DiCaro, A.; Li, Y.; Strong, J. E.; Aoki, F.; Plummer, F.; Jones, S. M.; Feldmann, H. Severe acute respiratory syndrome related coronavirus is inhibited by interferon-alpha. J. Infect. Dis. 2004, 189, 1164-1167.
203. Chu, C. M.; Cheng, V. C. C.; Hung, I. F. N.; Wong, M. M. L.; Chan, K. H.; Chan, K. S.; Kao, R. Y. T.; Poon, L. L. M.; Wong, C. L. P.; Guan, Y.; Peiris, J. S. M.; Yuen, K. Y. Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax 2004, 59, 252-256.
204. Tan, E. L. C.; Ooi, E. E.; Lin, C. Y.; Tan, H. C.; Ling, A. E.; Lim, B.; Stanton, L. W. Inhibition of SARS coronavirus infection in vitro with clinically approved antiviral drugs. Emerging Infect. Dis. 2004, 10, 581-586.
205. Knowles, S. R.; Phillips, E. J.; Dresser, L.; Matukas, L. Common adverse events associated with the use of ribavirin for severe acute respiratory syndrome in Canada. Clin. Infect. Dis. 2003, 37, 1139-1142.
206. van Vonderen, M. G. A.; Bos, J. C.; Prins, J. M.; Wertheim-van Dillen, P.; Speelman, P. Ribavirin in the treatment of severe acute respiratory syndrome (SARS). Neth. J. Med. 2003, 61, 238-241.
207. Fujii, T.; Nakamura, T.; Iwamoto, A. Current concepts in SARS treatment. J. Infect. Chemother. 2004, 10, 1-7.
208. Yamamoto, N.; Yang, R. G.; Yoshinaka, Y.; Amari, S.; Nakano, T.; Cinatl, J.; Rabenau, H.; Doerr, H. W.; Hunsmann, G.; Otaka, A.; Tamamura, H.; Fujii, N.; Yamamoto, N. HIV protease inhibitor nelfinavir inhibits replication of SARS-associated coronavirus. Biochem. Biophys. Res. Commun. 2004, 318, 719-725.
209. Chan, K. S.; Lai, S. T.; Chu, C. M.; Tsui, E.; Tam, C. Y.; Wong, M. M.; Tse, M. W.; Que, T. L.; Peiris, J. S.; Sung, J.; Wong, V. C.; Yuen, K. Y. Treatment of severe acute respiratory syndrome with lopinavir/ritonavir: a multicentre retrospective matched cohort study. Hong Kong Med. J. 2003, 9, 399-406.
210. Cinatl, J.; Morgenstern, B.; Bauer, G.; Chandra, P.; Rabenau, H.; Doerr, H. W. Treatment of SARS with human interferons. Lancet 2003, 362, 293-294.
211. Haagmans, B. L.; Kuiken, T.; Martina, B. E.; Fouchier, R. A. M.; Rimmelzwaan, G. F.; van Amerongen, G.; van Riel, D.; de Jong, T.; Itamura, S.; Chan, K. H.; Tashiro, M.; Osterhaus, A. D. M. E. Pegylated interferon-alpha protects type 1 pneumocytes against SARS coronavirus infection in macaques. Nat. Med. 2004, 10, 290-293.
212. Martina, B. E. E.; Haagmans, B. L.; Kuiken, T.; Fouchier, R. A. M.; Rimmelzwaan, G. F.; van Amerongen, G.; Peiris, J. S. M.; Lim, W.; Osterhaus, A. D. M. E. SARS virus infection of cats and ferrets. Nature 2003, 425, 915.
213. Enserink, M. Infectious diseases-SARS researchers report new animal models. Science 2003, 302, 213.
214. Rota, P. A.; Oberste, M. S.; Monroe, S. S.; Nix, W. A.; Campagnoli, R.; Icenogle, J. P.; Penaranda, S.; Bankamp, B.; Maher, K.; Chen, M. H.; Tong, S. X.; Tamin, A.; Lowe, L.; Frace, M.; DeRisi, J. L.; Chen, Q.; Wang, D.; Erdman, D. D.; Peret, T. C. T.; Burns, C.; Ksiazek, T. G.; Rollin, P. E.; Sanchez, A.; Liffick, S.; Holloway, B.; Limor, J.; McCaustland, K.; Olsen-Rasmussen, M.; Fouchier, R.; Gunther, S.; Osterhaus, A. D. M. E.; Drosten, C.; Pallansch, M. A.; Anderson, L. J.; Bellini, W. J. Characterization of a novel coronavirus associated with severe acute respiratory syndrome. Science 2003, 300, 1394-1399.
215. Marra, M. A.; Jones, S. J. M.; Astell, C. R.; Holt, R. A.; Brooks-Wilson, A.; Butterfield, Y. S. N.; Khattra, J.; Asano, J. K.; Barber, S. A.; Chan, S. Y.; Cloutier, A.; Coughlin, S. M.; Freeman, D.; Girn, N.; Griffin, O. L.; Leach, S. R.; Mayo, M.; McDonald, H.; Montgomery, S. B.; Pandoh, P. K.; Petrescu, A. S.; Robertson, A. G.; Schein, J. E.; Siddiqui, A.; Smailus, D. E.; Stott, J. E.; Yang, G. S.; Plummer, F.; Andonov, A.; Artsob, H.; Bastien, N.; Bernard, K.; Booth, T. F.; Bowness, D.; Czub, M.; Drebot, M.; Fernando, L.; Flick, R.; Garbutt, M.; Gray, M.; Grolla, A.; Jones, S.; Feldmann, H.; Meyers, A.; Kabani, A.; Li, Y.; Normand, S.; Stroher, U.; Tipples, G. A.; Tyler, S.; Vogrig, R.; Ward, D.; Watson, B.; Brunham, R. C.; Krajden, M.; Petric, M.; Skowronski, D. M.; Upton, C.; Roper, R. L. The genome sequence of the SARS-associated coronavirus. Science 2003, 300, 1399-1404.
216. Ruan, Y. J.; Wei, C. L.; Ee, L. A.; Vega, V. B.; Thoreau, H.; Yun, S. T. S.; Chia, J. M.; Ng, P.; Chiu, K. P.; Lim, L.; Tao, Z.; Peng, C. K.; Ean, L. O. L.; Lee, N. M.; Sin, L. Y.; Ng, L. F. P.; Chee, R. E.; Stanton, L. W.; Long, P. M.; Liu, E. T. Comparative full-length genome sequence analysis of 14 SARS coronavirus isolates and common mutations associated with putative origins of infection. Lancet 2003, 361, 1779-1785.
217. Snijder, E. J.; Bredenbeek, P. J.; Dobbe, J. C.; Thiel, V.; Ziebuhr, J.; Poon, L. L. M.; Guan, Y.; Rozanov, M.; Spaan, W. J. M.; Gorbalenya, A. E. Unique and conserved features of genome and proteome of SARS-coronavirus, an early split-off from the coronavirus group 2 lineage. J. Mol. Biol. 2003, 331, 991-1004.
218. Thiel, V.; Ivanov, K. A.; Putics, A.; Hertzig, T.; Schelle, B.; Bayer, S.; Weissbrich, B.; Snijder, E. J.; Rabenau, H.; Doerr, H. W.; Gorbalenya, A. E.; Ziebuhr, J. Mechanisms and enzymes involved in SARS coronavirus genome expression. J. Gen. Virol. 2003, 84, 2305-2315.
219. Liu, S. Q.; Guo, T.; Li, X. L.; Sun, Z. R. Bioinformatical study on the proteomics and evolution of SARS-CoV. Chin. Sci. Bull. 2003, 48, 1277-1287.
220. Holmes, K. V. SARS coronavirus: a new challenge for prevention and therapy. J. Clin. Invest. 2003, 111, 1605-1609.
221. Xu, X.; Liu, Y. Q.; Weiss, S.; Arnold, E.; Sarafianos, S. G.; Ding, J. P. Molecular model of SARS coronavirus polymerase: implications for biochemical functions and drug design. Nucleic Acids Res. 2003, 31, 7117-7130.
222. ' viral helicases. J. Biol. Chem. 2003, 278, 39578-39582.
223. Yan, L.; Velikanov, M.; Flook, P.; Zheng, W. J.; Szalma, S.; Kahn, S. Assessment of putative protein targets derived from the SARS genome. FEBS Lett. 2003, 554, 257-263.
224. Zhang, Y.; Xu, J. Y.; Deng, W.; Zhang, N.; Cai, L.; Zhao, Y.; Bu, D.; Chen, R. S. siRNA designs to the crucial proteins of SARS coronavirus. Prog. Biochem. Biophys. 2003, 30, 335-338.
225. pro) structure: basis for design of anti-SARS drugs. Science 2003, 300, 1763-1767.
226. Xiong, B.; Gui, C. S.; Xu, X. Y.; Luo, C.; Chen, J.; Luo, H. B.; Chen, L. L.; Li, G. W.; Sun, T.; Yu, C. Y.; Yue, L. D.; Duan, W. H.; Shen, J. K.; Qin, L.; Shi, T. L.; Li, Y. X.; Chen, K. X.; Luo, X. M.; Shen, X.; Shen, J. H.; Jiang, H. L. A 3D model of SARS-CoV 3CL proteinase and its inhibitors design by virtual screening. Acta Pharmacol. Sin. 2003, 24, 497-504.
227. Gao, X. F.; Xi, Z.; Huang, X. R.; Sun, C. C. 3D modeling of SARS virus proteinase and study of imaginable peptide inhibitor. Chem. J. Chin. Univ.-Chin. 2003, 24, 2279-2281.
228. Takeda-Shitaka, M.; Takaya, D.; Chiba, C.; Tanaka, H.; Umeyama, H. Protein structure prediction in structure based drug design. Curr. Med. Chem. 2004, 11, 551-558.
229. Takeda-Shitaka, M.; Nojima, H.; Takaya, D.; Kanou, K.; Iwadate, M.; Umeyama, H. Evaluation of homology modeling of the severe acute respiratory syndrome (SARS) coronavirus main protease for structure based drug design. Chem. Pharm. Bull. 2004, 52, 643-645.
230. Chou, K. C.; Wei, D. Q.; Zhong, W. Z. Binding mechanism of coronavirus main proteinase with ligands and its implication to drug design against SARS. Biochem. Biophys. Res. Commun. 2003, 308, 148-151.
231. Jenwitheesuk, E.; Samudrala, R. Identifying inhibitors of the SARS coronavirus proteinase. Bioorg. Med. Chem. Lett. 2003, 13, 3989-3992.
232. Toney, J. H.; Navas-Martin, S.; Weiss, S. R.; Koeller, A. Sabadinine: a potential nonpeptide anti-severe acute respiratory-syndrome agent identified using structure-aided design. J. Med. Chem. 2004, 47, 1079-1080.
233. Clarke, T. Nature 2003, (Science Update), http://www.nature.com/nsu/030512-030512-11.html.
234. Yang, H. T.; Yang, M. J.; Ding, Y.; Liu, Y. W.; Lou, Z. Y.; Zhou, Z.; Sun, L.; Mo, L. J.; Ye, S.; Pang, H.; Gao, G. F.; Anand, K.; Bartlam, M.; Hilgenfeld, R.; Rao, Z. H. The crystal structures of severe acute respiratory syndrome virus main protease and its complex with an inhibitor. Proc. Natl. Acad. Sci. U.S.A. 2003, 100, 13190-13195.
235. Fan, K. Q.; Wei, P.; Feng, Q.; Chen, S. D.; Huang, C. K.; Ma, L.; Lai, B.; Pei, J. F.; Liu, Y.; Chen, J. G.; Lai, L. H. Biosynthesis, purification, and substrate specificity of severe acute respiratory syndrome coronavirus 3C-like proteinase. J. Biol. Chem. 2004, 279, 1637-1642.
236. pro. Biochemistry 2004, 43, 4906-4912.
237. Xiao, X. D.; Chakraborti, S.; Dimitrov, A. S.; Gramatikoff, K.; Dimitrov, D. S. The SARS-CoV S glycoprotein: expression and functional characterization. Biochem. Biophys. Res. Commun. 2003, 312, 1159-1164.
238. Li, W. H.; Moore, M. J.; Vasilieva, N.; Sui, J. H.; Wong, S. K.; Berne, M. A.; Somasundaran, M.; Sullivan, J. L.; Luzuriaga, K.; Greenough, T. C.; Choe, H.; Farzan, M. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature 2003, 426, 450-454.
239. Simmons, G.; Reeves, J. D.; Rennekamp, A. J.; Amberg, S. M.; Piefer, A. J.; Bates, P. Characterization of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) spike glycoprotein-mediated viral entry. Proc. Natl. Acad. Sci. U.S.A. 2004, 101, 4240-4245.
240. Prabakaran, P.; Mao, X. D.; Dimitrov, D. S. A model of the ACE2 structure and function as a SARS-CoV receptor. Biochem. Biophys. Res. Commun. 2004, 314, 235-241.
241. Liu, S. W.; Xiao, G. F.; Chen, Y. B.; He, Y. X.; Niu, J. K.; Escalante, C. R.; Xiong, H. B.; Farmar, J.; Debnath, A. K.; Tien, P.; Jiang, S. B. Interaction between heptad repeat 1 and 2 regions in spike protein of SARS-associated coronavirus: implications for virus fusogenic mechanism and identification of fusion inhibitors. Lancet 2004, 363, 938-947.
242. Sui, J. H.; Li, W. H.; Murakami, A.; Tamin, A.; Matthews, L. J.; Wong, S. K.; Moore, M. J.; Tallarico, A. S. C.; Olurinde, M.; Choe, H.; Anderson, L. J.; Bellini, W. J.; Farzan, M.; Marasco, W. A. Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human mAb to S1 protein that blocks receptor association. Proc. Natl. Acad. Sci. U.S.A. 2004, 101, 2536-2541.
243. Zhang, Y. J.; Li, T. S.; Fu, L.; Yu, C. M.; Li, Y. H.; Xu, X. L.; Wang, Y. Y.; Ning, H. X.; Zhang, S. P.; Chen, W.; Babiuk, L. A.; Chang, Z. J. Silencing SARS-CoV spike protein expression in cultured cells by RNA interference. FEBS Lett. 2004, 560, 141-146.
244. He, M. L.; Zheng, B. J.; Peng, Y.; Peiris, J. S. M.; Poon, L. L. M.; Yuen, K. Y.; Lin, M. C. M.; Kung, H. F.; Guan, Y. Inhibition of SARS-associated coronavirus infection and replication by RNA interference. JAMA 2003, 290, 2665-2666.
245. Elmen, J.; Wahlestedt, C.; Brytting, M.; Wahren, B.; Ljungberg, K. SARS virus inhibited by siRNA. Preclinica 2004, 2, 135-142.
246. Morrey, J. D.; Day, C. W.; Julander, J. G.; Blatt, L. M.; Smee, D. F.; Sidwell, R. W. Effect of Interferon-alpha and interferon-inducers on West Nile virus in mouse and hamster animal models. Antiviral Chem. Chemother. 2004, 15, 67-75.
247. Solomon, T. Recent advances in Japanese encephalitis. J. Neurovirol. 2003, 9, 274-283.
248. Solomon, T.; Dung, N. M.; Wills, B.; Kneen, R.; Gainsborough, M.; Diet, T. V.; Thuy, T. T. N.; Loan, H. T.; Khanh, V. C.; Vaughn, D. W.; White, N. J.; Farrar, J. J. Interferon alpha-2a in Japanese encephalitis: a randomized double-blind placebo-controlled trial. Lancet 2003, 361, 821-826.
249. Block, T. M.; Jordan, R. Iminosugars as possible broad spectrum anti hepatitis virus agents: the glucovirs and alkovirs. Antiviral Chem. Chemother. 2001, 12, 317-325.
250. Mehta, A.; Zitzmann, N.; Rudd, P. M.; Block, T. M. α-Glucosidase inhibitors as potential broad based antiviral agents. FEBS Lett. 1998, 430, 17-22.
251. Wu, S. F.; Lee, C. J.; Liao, C. L.; Dwek, R. A.; Zitzmann, N.; Lin, Y. L. Antiviral effects of an iminosugar derivative on flavivirus infections. J. Virol. 2002, 76, 3596-3604.
252. Shi, P. Y. Genetic systems of West Nile virus and their potential applications. Curr. Opin. Invest. Drugs 2003, 4, 959-965.
253. Woodmansee, A. N.; Shi, P. Y. Recent developments in West Nile virus vaccine and antiviral therapy. Expert Opin. Ther. Patents 2003, 13, 1113-1125.
254. Borowski, P.; Niebuhr, A.; Schmitz, H.; Hosmane, R. S.; Bretner, M.; Siwecka, M. A.; Kulikowski, T. NTPase/helicase of Flaviviridae: inhibitors and inhibition of the enzyme. Acta Biochim. Pol. 2002, 49, 597-614.
255. Borowski, P.; Niebuhr, A.; Mueller, O.; Bretner, M.; Felczak, K.; Kulikowski, T.; Schmitz, H. Purification and characterization of West Nile virus nucleoside triphosphatase (NTPase)/helicase: evidence for dissociation of the NTPase and helicase activities of the enzyme. J. Virol. 2001, 75, 3220-3229.
256. Borowski, P.; Lang, M.; Haag, A.; Schmitz, H.; Choe, J.; Chen, H. M.; Hosmane, R. S. Characterization of imidazo[4,5-d]pyridazine nucleosides as modulators of unwinding reaction mediated by West Nile virus nucleoside triphosphatase/helicase: evidence for activity on the level of substrate and/or enzyme. Antimicrob. Agents Chemother. 2002, 46, 1231-1239.
257. Zhang, N.; Chen, H. M.; Koch, V.; Schmitz, H.; Liao, C. L.; Bretner, M.; Bhadti, V. S.; Fattom, A. I.; Naso, R. B.; Hosmane, R. S.; Borowski, P. Ring-expanded (''fat'') nucleoside and nucleotide analogues exhibit potent in vitro activity against Flaviviridae NTPases/helicases, including those of the West Nile virus, hepatitis C virus, and Japanese encephalitis virus. J. Med. Chem. 2003, 46, 4149-4164.
258. Zhang, N.; Chen, H. M.; Koch, V.; Schmitz, H.; Minczuk, M.; Stepien, P.; Fattom, A. I.; Naso, R. B.; Kalicharran, K.; Borowski, P.; Hosmane, R. S. Potent inhibition of NTPase/helicase of the West Nile virus by ring-expanded (''fat'') nucleoside analogues. J. Med. Chem. 2003, 46, 4776-4789.
259. Borowski, P.; Deinert, J.; Schalinski, S.; Bretner, M.; Ginalski, K.; Kulikowski, T.; Shugar, D. Halogenated benzimidazoles and benzotriazoles as inhibitors of the NTPase/helicase activities of hepatitis C and related viruses. Eur. J. Biochem. 2003, 270, 1645-1653.
260. Murthy, H. M. K.; Clum, S.; Padmanabhan, R. Dengue virus NS3 serine protease-crystal structure and insights into interaction of the active site with substrates by molecular modeling and structural analysis of mutational effects. J. Biol. Chem. 1999, 274, 5573-5580.
261. Bartholomeusz, A.; Tomlinson, E.; Wright, P. J.; Birch, C.; Locarnini, S.; Weigold, H.; Marcuccio, S.; Holan, G. Use of a flavivirus RNA-dependent RNA polymerase assay to investigate the antiviral activity of selected compounds. Antiviral Res. 1994, 24, 341-350.
262. Shigeta, S.; Mori, S.; Kodama, E.; Kodama, J.; Takahashi, K.; Yamase, T. Broad spectrum anti-RNA virus activities of titanium and vanadium substituted polyoxotung-states. Antiviral Res. 2003, 58, 265-271.
263. Olsen, D. B.; Bhat, B.; Bosserman, M.; Carroll, S. S.; Colwell, L.; De Francesco, R.; Eldrup, A. B.; Flores, O.; Getty, K.; LaFemina, R.; MacCoss, M.; Migliaccio, G.; Simcoe, A. L.; Rutkowski, C. A.; Stahlhut, M. W.; Tomassini, J. E.; Wolanski, B. 2'-Modified nucleoside analogs as inhibitors of hepatitis C RNA replication. Antiviral Res. 2003, 57, A76.
264. Nawa, M.; Takasaki, T.; Yamada, K. I.; Kurane, I.; Akatsuka, T. Interference in Japanese encephalitis virus infection of Vero cells by a cationic amphiphilic drug, chlorproma-zine. J. Gen. Virol. 2003, 84, 1737-1741.
265. Andoh, T.; Kawamata, H.; Umatake, M.; Terasawa, K.; Takegami, T.; Ochiai, H. Effect of bafilomycin A1 on the growth of Japanese encephalitis virus in Vero cells. J. Neurovirol. 1998, 4, 627-631.
266. Sanchez, I.; Gomez-Garibay, F.; Taboada, J.; Ruiz, B. H. Antiviral effect of flavonoids on the dengue virus. Phytother. Res. 2000, 14, 89-92.
267. Damonte, E. B.; Pujol, C. A.; Noseda, M.; Ciancia, N.; Matulewicz, M. C.; Cerezo, A. S. Potent and selective inhibition of dengue virus by carrageenans. Antiviral Res. 2002, 53, A49.
268. Laille, M.; Gerald, F.; Debitus, C. In vitro antiviral activity on dengue virus of marine natural products. Cell. Mol. Life Sci. 1998, 54, 167-170.
269. Takegami, T.; Simamura, E.; Hirai, K. I.; Koyama, J. Inhibitory effect of furanonaphtho-quinone derivatives on the replication of Japanese encephalitis virus. Antiviral Res. 1998, 37, 37-45.
270. Kim, H.; Kim, S. J.; Park, S. N.; Oh, J. W. Antiviral effect of amphotericin B on Japanese encephalitis virus replication. J. Microbiol. Biotechnol. 2004, 14, 121-127.
271. Koff, W. C.; Elm, J. L.; Halstead, S. B. Inhibition of dengue virus replication by amantadine hydrochloride. Antimicrob. Agents Chemother. 1980, 18, 125-129.
272. Raviprakash, K.; Liu, K.; Matteucci, M.; Wagner, R.; Riffenburgh, R.; Carl, M. Inhibition of dengue virus by novel, modified antisense oligonucleotides. J. Virol. 1995, 69, 69-74.
273. Iversen, P. L.; Stein, D.; Kroeker, A.; Arora, V.; Barklis, E.; Hill, A.; Smith, A.; Wallace, R. Rapid development of an antisense phosphorodiamidate morpholino oligomer for the treatment of West Nile virus. Antiviral Res. 2004, 62, A32-A33.
274. Shi, P. Y.; Tilgner, M.; Lo, M. K. Construction and characterization of subgenomic replicons of New York strain of West Nile virus. Virology 2002, 296, 219-233.
275. Shi, P. Y.; Tilgner, M.; Lo, M. K.; Kent, K. A.; Bernard, K. A. Infectious cDNA clone of the epidemic West Nile virus from New York City. J. Virol. 2002, 76, 5847-5856.
276. Lo, M. K.; Tilgner, M.; Shi, P. Y. Potential high-throughput assay for screening inhibitors of West Nile virus replication. J. Virol. 2003, 77, 12901-12906.
277. Shi, P. Y. Strategies for the identification of inhibitors of West Nile virus and other flaviviruses. Curr. Opin. Invest. Drugs 2002, 3, 1567-1573.
278. Sidwell, R. W.; Smee, D. F. Viruses of the Bunya-and Togaviridae families: potential as bioterrorism agents and means of control. Antiviral Res. 2003, 57, 101-111.
279. +-ATPase in animal virus entry. J. Gen. Virol. 1994, 75, 2595-2606.
280. Perez, L.; Carrasco, L. Entry of poliovirus into cells does not require a low-pH step. J. Virol. 1993, 67, 4543-4548.
281. Guinea, R.; Carrasco, L. Concanamycin-A-a powerful inhibitor of enveloped animal-virus entry into cells. Biochem. Biophys. Res. Commun. 1994, 201, 1270-1278.
282. Irurzun, A.; Nieva, J. L.; Carrasco, L. Entry of Semliki Forest virus into cells: effects of concanamycin A and nigericin on viral membrane fusion and infection. Virology 1997, 227, 488-492.
283. Jahrling, P. B.; Hesse, R. A.; Rhoderick, J. B.; Elwell, M. A.; Moe, J. B. Pathogenesis of a Pichinde virus strain adapted to produce lethal infections in guinea pigs. Infect. Immun. 1981, 32, 872-880.
284. Liu, C. T.; Griffin, M. J.; Jahrling, P. B.; Peters, C. J. Physiologic and pharmacologic treatments of Pichinde virus infection in strain 13 guinea pigs. Fed. Proc. 1985, 44, 1836.
285. Perez, M.; Craven, R. C.; de la Torre, J. C. The small RING finger protein Z drives arenavirus budding: implications for antiviral strategies. Proc. Natl. Acad. Sci. U.S.A. 2003, 100, 12978-12983.
286. Lopez, N.; Jacamo, R.; Franze-Fernandez, M. T. Transcription and RNA replication of Tacaribe virus genome and antigenome analogs require N and L proteins: Z protein is an inhibitor of these processes. J. Virol. 2001, 75, 12241-12251.
287. Jacamo, R.; Lopez, N.; Wilda, M.; Franze-Fernandez, M. T. Tacaribe virus Z protein interacts with the L polymerase protein to inhibit viral RNA synthesis. J. Virol. 2003, 77, 10383-10393.
288. Cornu, T. I.; de la Torre, J. C. Characterization of the arenavirus RING finger Z protein regions required for Z-mediated inhibition of viral RNA synthesis. J. Virol. 2002, 76, 6678-6688.
289. Garcia, C. C.; Candurra, N. A.; Damonte, E. B. Antiviral and virucidal activities against arenaviruses of zinc-finger active compounds. Antiviral Chem. Chemother. 2000, 11, 231-237.
290. Garcia, C. C.; Candurra, N. A.; Damonte, E. B. Mode of inactivation of arenaviruses by disulfide-based compounds. Antiviral Res. 2002, 55, 437-446.
291. Garcia, C. C.; Candurra, N. A.; Damonte, E. B. Differential inhibitory action of two azoic compounds against arenaviruses. Int. J. Antimicrob. Agents 2003, 21, 319-324.
292. Bartolotta, S.; Garcia, C. C.; Candurra, N. A.; Damonte, E. B. Effect of fatty acids on arenavirus replication: inhibition of virus production by lauric acid. Arch. Virol. 2001, 146, 777-790.
293. Cordo, S. M.; Candurra, N. A.; Damonte, E. B. Myristic acid analogs are inhibitors of Junin virus replication. Microbes Infect. 1999, 1, 609-614.
294. Candurra, N. A.; Maskin, L.; Damonte, E. B. Inhibition of arenavirus multiplication in vitro by phenotiazines. Antiviral Res. 1996, 31, 149-158.
295. Ruiz-Jarabo, C. M.; Ly, C.; Domingo, E.; de la Torre, J. C. Lethal mutagenesis of the prototypic arenavirus lymphocytic choriomeningitis virus (LCMV). Virology 2003, 308, 37-47.
296. Xing, Z.; Whitton, J. L. Ribozymes which cleave arenavirus RNAs-identification of susceptible target sites and inhibition by target site secondary structure. J. Virol. 1992, 66, 1361-1369.
297. Xing, Z.; Whitton, J. L. An anti-lymphocytic choriomeningitis virus ribozyme expressed in tissue culture cells diminishes viral RNA levels and leads to a reduction in infectious virus yield. J. Virol. 1993, 67, 1840-1847.
298. Kunz, S.; Borrow, P.; Oldstone, M. B. A. Receptor structure, binding, and cell entry of arenaviruses. Arenaviruses I 2002, 262, 111-137.
299. Spiropoulou, C. F.; Kunz, S.; Rollin, P. E.; Campbell, K. P.; Oldstone, M. B. A. New World arenavirus clade C, but not clade A and B viruses, utilizes alpha-dystroglycan as its major receptor. J. Virol. 2002, 76, 5140-5146.
300. Cao, W.; Henry, M. D.; Borrow, P.; Yamada, H.; Elder, J. H.; Ravkov, E. V.; Nichol, S. T.; Compans, R. W.; Campbell, K. P.; Oldstone, M. B. A. Identification of alpha-dystroglycan as a receptor for lymphocytic choriomeningitis virus and Lassa fever virus. Science 1998, 282, 2079-2081.
301. Wachsman, M. B.; Lopez, E. M. F.; Ramirez, J. A.; Galagovsky, L. R.; Coto, C. E. Antiviral effect of brassinosteroids against herpes virus and arenaviruses. Antiviral Chem. Chemother. 2000, 11, 71-77.
302. Garcia, C. C.; Rosso, M. L.; Bertoni, M. D.; Maier, M. S.; Damonte, E. B. Evaluation of the antiviral activity against Junin virus of macrocyclic trichothecenes produced by the hypocrealean epibiont of Baccharis coridifolia. Planta Med. 2002, 68, 209-212.
303. Uckun, F. M.; Petkevich, A. S.; Vassilev, A. O.; Tibbles, H. E.; Titov, L. Stampidine prevents mortality in an experimental mouse model of viral hemorrhagic fever caused by Lassa virus. BMC Infect. Dis. 2004, 4, art-1.
304. Khan, A. S.; Young, J. C. Hantavirus pulmonary syndrome: at the crossroads. Curr. Opin. Infect. Dis. 2001, 14, 205-209.
305. Sidwell, R. W.; Huffman, J. H.; Barnard, D. L.; Pifat, D. Y. Effects of ribamidine, a 3-carboxamidine derivative of ribavirin, on experimentally induced Phlebovirus infections. Antiviral Res. 1988, 10, 193-207.
306. Fisher, A. F.; Tesh, R. B.; Tonry, J.; Guzman, H.; Liu, D. Y.; Xiao, S. Y. Induction of severe disease in hamsters by two sandfly fever group viruses, Punta Toro and Gabek Forest (Phlebovirus, Bunyaviridae), similar to that caused by Rift Valley fever virus. Am. J. Trop. Med. Hyg. 2003, 69, 269-276.
307. Bray, M.; Davis, K.; Geisbert, T.; Schmaljohn, C.; Huggins, J. A mouse model for evaluation of prophylaxis and therapy of Ebola hemorrhagic fever. J. Infect. Dis. 1998, 178, 651-661.
308. Smee, D. F.; Bray, M.; Huggins, J. W. Intracellular phosphorylation of carbocyclic 3-deazaadenosine, an anti-Ebola virus agent. Antiviral Chem. Chemother. 2001, 12, 251-258.
309. Bray, M.; Driscoll, J.; Huggins, J. W. Treatment of lethal Ebola virus infection in mice with a single dose of an S-adenosyl-L-homocysteine hydrolase inhibitor. Antiviral Res. 2000, 45, 135-147.
310. Bray, M.; Raymond, J. L.; Geisbert, T.; Baker, R. O. 3-Deazaneplanocin A induces massively increased interferon-alpha production in Ebola virus-infected mice. Antiviral Res. 2002, 55, 151-159.
311. Bray, M. Defense against filoviruses used as biological weapons. Antiviral Res. 2003, 57, 53-60.
312. Trampuz, A.; Prabhu, R. M.; Smith, T. F.; Baddour, L. M. Avian influenza: a new pandemic threat. Mayo Clin. Proc. 2004, 79, 523-530.
313. Krug, R. M. The potential use of influenza virus as an agent for bioterrorism. Antiviral Res. 2003, 57, 147-150.
314. Gubareva, L. V.; Penn, C. R.; Webster, R. G. Inhibition of replication of avian influenza viruses by the neuraminidase inhibitor 4-guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid. Virology 1995, 212, 323-330.
315. Gubareva, L. V.; McCullers, J. A.; Bethell, R. C.; Webster, R. G. Characterization of influenza A/HongKong/156/97 (H5N1) virus in a mouse model and protective effect of zanamivir on H5N1 infection in mice. J. Infect. Dis. 1998, 178, 1592-1596.
316. Leneva, I. A.; Roberts, N.; Govorkova, E. A.; Goloubeva, O. G.; Webster, R. G. The neuraminidase inhibitor GS4104 (oseltamivir phosphate) is efficacious against A/Hong Kong/156/97 (H5N1) and A/Hong Kong/1074/99 (H9N2) influenza viruses. Antiviral Res. 2000, 48, 101-115.
317. Govorkova, E. A.; Leneva, I. A.; Goloubeva, O. G.; Bush, K.; Webster, R. G. Comparison of efficacies of RWJ-270201, zanamivir, and oseltamivir against H5N1, H9N2, and other avian influenza viruses. Antimicrob. Agents Chemother. 2001, 45, 2723-2732.
318. Brooks, M. J.; Sasadeusz, J. J.; Tannock, G. A. Antiviral chemotherapeutic agents against respiratory viruses: where are we now and what's in the pipeline? Curr. Opin. Pulm. Med. 2004, 10, 197-203.
319. Tseng, C.; Laughlin, C. Antiviral agents, RNA (viruses other than HIV), and orthopoxviruses. In Burger's Medicinal Chemistry and Drug Discovery, 6th ed., V.5, Abraham, D. (Ed.). John Wiley & Sons, Hoboken, NJ, 2003, pp 359-457.